These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 6420530)

  • 1. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.
    Isles A; Maclusky I; Corey M; Gold R; Prober C; Fleming P; Levison H
    J Pediatr; 1984 Feb; 104(2):206-10. PubMed ID: 6420530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    J Antimicrob Chemother; 1985 May; 15(5):545-9. PubMed ID: 3924879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    Antimicrob Agents Chemother; 1984 Feb; 25(2):279-80. PubMed ID: 6561954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas cepacia in the sputum of cystic fibrosis patients.
    Taylor PC; Kalamatianos CC
    Pathology; 1994 Jul; 26(3):315-7. PubMed ID: 7527513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
    Gold R; Jin E; Levison H; Isles A; Fleming PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia.
    Taylor RF; Gaya H; Hodson ME
    J Antimicrob Chemother; 1992 Mar; 29(3):341-4. PubMed ID: 1375595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Dunne WM; Chusid MJ
    Diagn Microbiol Infect Dis; 1987 Feb; 6(2):165-70. PubMed ID: 3102157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.
    Cheng K; Smyth RL; Govan JR; Doherty C; Winstanley C; Denning N; Heaf DP; van Saene H; Hart CA
    Lancet; 1996 Sep; 348(9028):639-42. PubMed ID: 8782753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group.
    Pegues DA; Carson LA; Tablan OC; FitzSimmons SC; Roman SB; Miller JM; Jarvis WR
    J Pediatr; 1994 May; 124(5 Pt 1):694-702. PubMed ID: 7513755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriophages in sputum of cystic fibrosis patients as a possible cause of in vivo changes in serotypes of Pseudomonas aeruginosa.
    Ojeniyi B
    APMIS; 1988 Apr; 96(4):294-8. PubMed ID: 3130885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.
    Bauernfeind A; Emminger G; Hörl G; Ott S; Przyklenk B; Weisslein-Pfister C
    Infection; 1987; 15(5):403-6. PubMed ID: 3121519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas cepacia in cystic fibrosis patients.
    Prince A
    Am Rev Respir Dis; 1986 Oct; 134(4):644-5. PubMed ID: 3094414
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Caplan DB; Buchanan CN
    Rev Infect Dis; 1984; 6 Suppl 3():S705-10. PubMed ID: 6443771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pH and CO2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams.
    Corkill JE; Deveney J; Pratt J; Shears P; Smyth A; Heaf D; Hart CA
    Pediatr Res; 1994 Mar; 35(3):299-302. PubMed ID: 7514780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
    Dalzell AM; Sunderland D; Hart CA; Heaf DP
    Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ceftazidime against Pseudomonas aeruginosa from bacteraemic and fibrocystic patients.
    Fleming PC; Knie B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():169-73. PubMed ID: 19802981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis.
    Vogelberg C; Hirsch T; Rösen-Wolff A; Kerkmann ML; Leupold W
    Pediatr Pulmonol; 2003 Oct; 36(4):348-52. PubMed ID: 12950050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AP-PCR typing of Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Giordano A; Magni A; Graziani C; Sessa R; Quattrucci S; Cipriani P
    New Microbiol; 2001 Apr; 24(2):157-63. PubMed ID: 11346299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.